Brief: Teva And MedinCell Announce FDA Acceptance Of New Drug Application For TV-46000/mdc-IRM As A Treatment For Patients With Schizophrenia
31/08/2021 21:19
Aug 31 (Reuters) - Medincell SA MEDCL.PA :
* TEVA AND MEDINCELL ANNOUNCE FDA ACCEPTANCE OF NEW DRUG
APPLICATION FOR TV-46000/MDC-IRM AS A TREATMENT FOR PATIENTS
WITH SCHIZOPHRENIA
Source text for Eikon: ID:nBw2vtFNXa
Further company coverage: MEDCL.PA
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris